The Vitiligo drugs in development market research report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vitiligo. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vitiligo and features dormant and discontinued products.
GlobalData tracks 53 drugs in development for Vitiligo by 48 companies/universities/institutes. The top development phase for Vitiligo is preclinical with 16 drugs in that stage. The Vitiligo pipeline has 50 drugs in development by companies and three by universities/ institutes. Some of the companies in the Vitiligo pipeline products market are: Alys Pharmaceuticals, National Research Council of Canada and Pfizer.
The key targets in the Vitiligo pipeline products market include Tyrosine Protein Kinase JAK1, Tyrosine Protein Kinase JAK3, and Janus Kinase.
The key mechanisms of action in the Vitiligo pipeline product include Tyrosine Protein Kinase JAK1 Inhibitor with seven drugs in Phase III. The Vitiligo pipeline products include nine routes of administration with the top ROA being Topical and 11 key molecule types in the Vitiligo pipeline products market including Small Molecule, and Monoclonal Antibody.
Vitiligo overview
Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair, and eyes. Symptoms include premature whitening or graying of the hair on teh scalp, eyelashes, eyebrows, or beard; loss of color in the tissues that line the inside of mouth; and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators, and surgery.
For a complete picture of Vitiligo’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
